Pentwater Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Pentwater Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-4,933,200	Closed	-$906M	–	355
2021 Q2	$906M	Buy	4,933,200 +643,956	+15%	+$111M	7.48%	3
2021 Q1	$656M	Buy	4,289,244 +1,328,244	+45%	+$205M	6.26%	4
2020 Q4	$463M	Buy	+2,961,000	New	+$380M	5.59%	6
2019 Q4	–	Sell	-22,500	Closed	-$2.2M	–	190
2019 Q3	$2.2M	Buy	+22,500	New	+$2.54M	0.03%	89
2017 Q1	–	Sell	-6,000	Closed	-$734K	–	126
2016 Q4	$734K	Buy	+6,000	New	+$734K	0.01%	108

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Pentwater Capital Management's ALXN Position: Q3 2021 in Review

Pentwater Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,933,200 shares — an estimated $906M sold.

Pentwater Capital Management first reported a position in ALXN in Q4 2016 and held it in 5 quarters. The position peaked at $906M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Pentwater Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Pentwater Capital Management sold 4,933,200 Alexion Pharmaceuticals shares in Q3 2021, an estimated $906M.
Pentwater Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 5 quarters.
Pentwater Capital Management's Alexion Pharmaceuticals position peaked at $906M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Pentwater Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.